Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Zavanna Announces Equity Investment From Carnelian Energy Capital
-
Dimensional Fund Advisors Ltd. : Form 8.3 - ASCENTIAL PLC - Ordinary Shares
-
Announcement of drawings (CK95) - Nykredit Realkredit A/S
-
Man Group PLC : Form 8.3 - Keywords Studios plc
-
Man Group PLC : Form 8.3 - Darktrace plc
-
Man Group PLC : Form 8.3 - TI Fluid Systems plc
-
Man Group PLC : Form 8.3 - International Paper Company
-
Man Group PLC : Form 8.3 - AngloGold Ashanti plc
-
RESULT OF RIKSBANK CERTIFICATE SALE
-
The Global Panda Partners 2024 Scheduled to Take Place in Chengdu by End of November
-
Oxford-Harrington Rare Disease Centre to Host Symposium on Pioneering Research and Innovation in Rare Disease Treatments
-
Mabylon AG Receives Research Grants Totaling More Than CHF 1.3 Million for Amyotrophic Lateral Sclerosis (ALS) and Inflammasome Programs
-
Bitget Wallet Outlines Roadmap in TOKEN2049: Simplifying Web3 for the Next Billion Users
-
Invitation to conference call with web presentation of SkiStar AB's Year-End Report for 2023/24
-
West Red Lake Gold Intersects 49.39 g/t Au over 4.48m and 18.46 g/t Au over 11.2m at South Austin – Madsen Mine
-
New Hydrogen CEO Steve Hill and Dartmouth Energy Expert Discuss Scalable Nanomanufacturing and 2D Materials for Energy Applications
-
CONDITIONS FOR SALE OF RIKSBANK CERTIFICATES
-
Form 8.5 (EPT/RI) - Touchstone Exploration Inc.
-
Blueshift Selected by RCS MediaGroup to Revolutionize Multi-Channel Customer Engagement
-
Nokia selected by Spark as majority 5G RAN partner in New Zealand
-
Nokia and ZCorum collaborate to develop DOCSIS Provisioning Adapter for cable-to-fiber transition
-
HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda
-
AlgoTx Announces “Last Patient Last Visit” in International Phase II Trial of ATX01 in Chemotherapy-Induced Peripheral Neuropathy
-
Form 8.5 (EPT/RI) - NewRiver REIT Plc
-
Form 8.5 (EPT/RI) - Trinity Exploration & Production Plc
-
Groupe Casino: Changes in governance at Monoprix and Naturalia
-
Share buybacks in Spar Nord Bank – transactions in week 38
-
Second Well Delineates Heisenberg, Confirms Size of Discovery
-
Terranet reaches strategic milestone - achieves autonomous braking
-
Nxera Pharma Receives Approval of QUVIVIQ (daridorexant) 25 and 50 mg in Japan for the Treatment of Insomnia
-
Nxera Pharma Receives Approval of QUVIVIQ (daridorexant) 25 and 50 mg in Japan for the Treatment of Insomnia
-
Litchfield Hills Research raises its buy recommendation for Virtualware to €12 per share
-
Equinor ASA: Share buy-back
-
LIfT BioSciences raises £10m in first close of Series A to advance first-in-class allogeneic innate cell therapy
-
TRiCares Announces First Topaz Implantation in EU Pivotal Study
-
Financing Update – Important clarification
-
Progress on share buyback programme
-
Soitec: Soitec and Resonac announce the signing of a joint development agreement in SmartSiC™ to accelerate high-performance silicon carbide adoption in next-generation electric vehicles
-
Lleida.net covers 100% of its newest private purchase plan, in a transaction of more than 225,000 euros
-
Transaction in Own Shares
-
Haffner Energy teams up with Bambbco, France’s leading bamboo provider, to diversify sustainable biomass procurement
-
Sampo plc’s share buybacks 23 September 2024
-
BGHL (GBP): NAV(s)
-
BGHL (EUR): NAV(s)
-
Basilea initiates clinical phase 3 study with antifungal fosmanogepix in candidemia and invasive candidiasis
-
Belships ASA: Key information relating to the cash dividend to be paid by Belships ASA
-
Nature Reviews Highlights Significant Successes of Antibiotic Collaboration and Calls for Sustainable R&D Funding Schemes
-
UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024
-
Start of Day Message
-
Belships ASA: Extraordinary dividend payment
